NDATOPICALGEL
Approved
Jul 2015
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
EPIDUO FORTE (adapalene and benzoyl peroxide) by Galderma is protein. First approved in 2015.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EPIDUO FORTE is a topical gel combining adapalene (a retinoid that modulates cellular differentiation and inflammation) and benzoyl peroxide (an oxidizing agent with bactericidal and keratolytic properties) for the treatment of acne. It is applied topically and works through dual mechanisms to reduce acne lesions and associated inflammatory processes. This fixed-dose combination represents an advanced formulation in the retinoid-based acne treatment class.
$0.077BPart D
PeakProduct is in peak commercial phase with stable Medicare utilization; moderate team investment with focus on market penetration and patient adherence strategies.
Mechanism of Action
protein. Biochemical and pharmacological profile studies have demonstrated that adapalene is a modulator of cellular differentiation, keratinization and inflammatory processes. However, the significance of these findings with regard to the mechanism of action of adapalene for the treatment of acne…
Pharmacologic Class:
Retinoid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
EPIDUO FORTE positions career professionals in a mature, stable dermatology product with established market presence and predictable revenue streams. Working on this brand emphasizes commercial excellence, market penetration, and patient retention strategies in a competitive topical acne market rather than novel mechanism development.
Brand Manager
Worked on EPIDUO FORTE at Galderma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.